{"id":45559,"date":"2025-11-03T11:18:11","date_gmt":"2025-11-03T03:18:11","guid":{"rendered":"https:\/\/flcube.com\/?p=45559"},"modified":"2025-11-03T11:18:12","modified_gmt":"2025-11-03T03:18:12","slug":"cttq-deepens-partnership-with-shionogi-to-accelerate-naldemedine-launch-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45559","title":{"rendered":"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China"},"content":{"rendered":"\n<p><strong>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.<\/strong> (CTTQ), a core subsidiary of <strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>), announced an expanded cooperation agreement with <strong>Shionogi China\u202fCo., Ltd.<\/strong>. The joint effort will cover registration, regulatory approval, regional supply, medical\u2011support services, and commercial rollout of <strong>naldemedine<\/strong> across mainland China, with a focus on the Hainan Boao\u202fLecheng International Medical Tourism Pilot Zone and the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Scope<\/strong><\/td><td>Registration, NMPA approval, regional distribution, medical\u2011support, marketing<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>Hainan Boao\u202fLecheng Pilot Zone &amp; Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Fast\u2011track launch of naldemedine and build a rapid\u2011deployment platform for clinically urgent imported drugs<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>NDA for naldemedine accepted by the NMPA on <strong>29\u202fMay\u202f2025<\/strong><\/td><\/tr><tr><td><strong>Policy Leverage<\/strong><\/td><td>Utilisation of special\u2011policy incentives in Boao\u202fLecheng (clinical\u2011urgency pathway) and Greater Bay Area (tax &amp; customs facilitation)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-naldemedine\">About Naldemedine<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Peripherally acting \u03bc\u2011opioid receptor antagonist that reverses opioid\u2011induced constipation (OIC) by blocking opioid effects on the enteric nervous system, thereby normalising intestinal motility and secretion.<\/li>\n\n\n\n<li><strong>Global Approvals<\/strong> \u2013 United States (FDA), European Union (EMA), Japan (PMDA), Taiwan, Hong\u202fKong, and Macao.<\/li>\n\n\n\n<li><strong>China Status<\/strong> \u2013 Approved for clinical use in the Lecheng Branch of Hainan Provincial People\u2019s Hospital as a clinically urgent drug (2022). The formal Chinese NDA was accepted by the NMPA in May\u202f2025.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Regulatory Speed<\/strong> \u2013 Boao\u202fLecheng\u2019s \u201cclinically urgent\u201d pathway shortens the time from NDA acceptance to market entry, a critical advantage for a drug addressing a high\u2011unmet\u2011need indication.<\/li>\n\n\n\n<li><strong>Market Access<\/strong> \u2013 The Greater Bay Area\u2019s integrated customs and tax framework enables smoother cross\u2011border logistics, reducing lead times for imported biologics and specialty drugs.<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong> \u2013 For CTTQ, the partnership adds a best\u2011in\u2011class OIC therapy to its gastrointestinal pipeline; for Shionogi, it secures a reliable Chinese commercial partner with deep local expertise.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-outlook\">Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Launch Timeline<\/strong> \u2013 Both parties target a <strong>Q1\u202f2026<\/strong> commercial roll\u2011out in the Boao\u202fLecheng pilot zone, followed by phased expansion throughout the Greater Bay Area and nationwide distribution.<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong> \u2013 Market analysts estimate the Chinese OIC market to exceed <strong>$1.2\u202fB<\/strong> by 2028; naldemedine could capture a 10\u201115\u202f% share, translating to <strong>$120\u2011180\u202fM<\/strong> in annual sales.<\/li>\n\n\n\n<li><strong>Future Collaboration<\/strong> \u2013 The framework established for naldemedine is expected to serve as a template for other clinically urgent imported therapies, expanding the CTTQ\u2011Shionogi pipeline.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements that involve risks and uncertainties, including regulatory outcomes, market acceptance, and commercial performance. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45560,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[91,661,26,908,423,313],"class_list":["post-45559","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-boao-lecheng-pilot-zone","tag-chia-tai-tianqing-pharmaceutical","tag-greater-bay-area","tag-hkg-1177","tag-shionogi","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced an expanded cooperation agreement with Shionogi China\u202fCo., Ltd.. The joint effort will cover registration, regulatory approval, regional supply, medical\u2011support services, and commercial rollout of naldemedine across mainland China, with a focus on the Hainan Boao\u202fLecheng International Medical Tourism Pilot Zone and the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45559\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China\" \/>\n<meta property=\"og:description\" content=\"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced an expanded cooperation agreement with Shionogi China\u202fCo., Ltd.. The joint effort will cover registration, regulatory approval, regional supply, medical\u2011support services, and commercial rollout of naldemedine across mainland China, with a focus on the Hainan Boao\u202fLecheng International Medical Tourism Pilot Zone and the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45559\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T03:18:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-03T03:18:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0303.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45559#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45559\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China\",\"datePublished\":\"2025-11-03T03:18:11+00:00\",\"dateModified\":\"2025-11-03T03:18:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45559\"},\"wordCount\":430,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45559#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0303.webp\",\"keywords\":[\"Boao Lecheng pilot zone\",\"Chia Tai Tianqing Pharmaceutical\",\"Greater Bay Area\",\"HKG: 1177\",\"Shionogi\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45559#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45559\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45559\",\"name\":\"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45559#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45559#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0303.webp\",\"datePublished\":\"2025-11-03T03:18:11+00:00\",\"dateModified\":\"2025-11-03T03:18:12+00:00\",\"description\":\"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced an expanded cooperation agreement with Shionogi China\u202fCo., Ltd.. The joint effort will cover registration, regulatory approval, regional supply, medical\u2011support services, and commercial rollout of naldemedine across mainland China, with a focus on the Hainan Boao\u202fLecheng International Medical Tourism Pilot Zone and the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45559#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45559\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45559#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0303.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0303.webp\",\"width\":1080,\"height\":608,\"caption\":\"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45559#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China - Insight, China&#039;s Pharmaceutical Industry","description":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced an expanded cooperation agreement with Shionogi China\u202fCo., Ltd.. The joint effort will cover registration, regulatory approval, regional supply, medical\u2011support services, and commercial rollout of naldemedine across mainland China, with a focus on the Hainan Boao\u202fLecheng International Medical Tourism Pilot Zone and the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45559","og_locale":"en_US","og_type":"article","og_title":"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China","og_description":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced an expanded cooperation agreement with Shionogi China\u202fCo., Ltd.. The joint effort will cover registration, regulatory approval, regional supply, medical\u2011support services, and commercial rollout of naldemedine across mainland China, with a focus on the Hainan Boao\u202fLecheng International Medical Tourism Pilot Zone and the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area.","og_url":"https:\/\/flcube.com\/?p=45559","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-03T03:18:11+00:00","article_modified_time":"2025-11-03T03:18:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0303.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45559#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45559"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China","datePublished":"2025-11-03T03:18:11+00:00","dateModified":"2025-11-03T03:18:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45559"},"wordCount":430,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45559#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0303.webp","keywords":["Boao Lecheng pilot zone","Chia Tai Tianqing Pharmaceutical","Greater Bay Area","HKG: 1177","Shionogi","Sino Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45559#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45559","url":"https:\/\/flcube.com\/?p=45559","name":"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45559#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45559#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0303.webp","datePublished":"2025-11-03T03:18:11+00:00","dateModified":"2025-11-03T03:18:12+00:00","description":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced an expanded cooperation agreement with Shionogi China\u202fCo., Ltd.. The joint effort will cover registration, regulatory approval, regional supply, medical\u2011support services, and commercial rollout of naldemedine across mainland China, with a focus on the Hainan Boao\u202fLecheng International Medical Tourism Pilot Zone and the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45559#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45559"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45559#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0303.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0303.webp","width":1080,"height":608,"caption":"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45559#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0303.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45559"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45559\/revisions"}],"predecessor-version":[{"id":45561,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45559\/revisions\/45561"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45560"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}